Investigating how androgens affect liver health in young women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the impact of androgens on nonalcoholic fatty liver disease (NAFLD) in young women, particularly focusing on those with polycystic ovary syndrome (PCOS). Researchers will compare the progression of NAFLD over time between young women with PCOS and those without. The study hypothesizes that androgens contribute to liver injury and the progression of NAFLD/NASH through mechanisms involving lipid metabolism and visceral fat activity. The research is funded by the National Institutes of Health and involves collaboration between the University of California, San Francisco, and Duke University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Metabolic associated steatohepatitis (MASH) (formerly NASH)
* PCOS
* Non-PCOS

Exclusion Criteria:

* High levels of alcohol use (more than 7 drinks a week)
* Current pregnancy
* Other causes of hepatic steatosis
* Weight loss of more than 10% body weight in the last 6 months

Where it's running

• University of California San Francisco
  San Francisco, California, United States Recruiting
• Duke University
  Durham, North Carolina, United States Not yet recruiting

Study contacts

• Principal investigator: Monika A Sarkar, M.D., M.A.S — University of California, San Francisco
• Study coordinator: Lily C Carbullido, B.S.
• Email: myliverhealth@ucsf.edu
• Phone: 415-502-3725

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital prevention for liver disease management

  This study is testing a new way to help people with liver disease by using a mobile app for patients and a dashboard for doctors to see if it improves their care and health outcomes.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Lazio · NCT06879236

• Digoxin for NASH with stage 2–3 fibrosis

  This trial will see if taking once-daily digoxin helps clear NASH and reduce liver scarring in adults with biopsy-confirmed NASH and stage 2–3 fibrosis.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT06588699

• Very low-calorie ketogenic diet for patients with liver disease

  This study is testing whether a very low-calorie ketogenic diet can improve liver health and help with weight management in people with liver disease compared to a standard low-calorie Mediterranean diet.

  Recruiting University of Bologna · Bologna · NCT06308757

• Bicalutamide treatment for young women with liver disease and PCOS

  This study is testing if a medication called bicalutamide can help young women with liver disease and PCOS feel better and improve their liver health.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT05979389

• A registry for studying Non-Alcoholic Fatty Liver Disease in Europe

  This study is collecting health information and samples from people with Non-Alcoholic Fatty Liver Disease to learn more about the disease and find better ways to track its progress.

  Recruiting at 33 sites Newcastle University · Antwerp and 36 other locations · NCT04442334

• PMOS and Sleep Apnea: A Pilot Look at Mitochondrial Function

  In women with PMOS, this pilot study tests whether sleep apnea treatment with CPAP improves mitochondrial function in leg muscle tissue.

  Recruiting University of Chicago · Chicago, Illinois · NCT07871149

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.